Get the Finder app 🥳

Track your credit score, free

Free

How to buy BARD1 Life Sciences shares | A$0.027

Own BARD1 Life Sciences shares in just a few minutes.

Posted

Fact checked

BARD1 Life Sciences Limited is a diagnostics & research business based in Australia. BARD1 Life Sciences shares (BD1) are listed on the Australian Securities Exchange (ASX) and all prices are listed in Australian Dollars. Its last market close was $0.027 – a decrease of 3.57% over the previous week. BARD1 Life Sciences has a trailing 12-month revenue of around $464,101.

How to buy shares in BARD1 Life Sciences

  1. Compare share trading platforms. To buy shares listed in Australia, you'll need to sign up to a broker with access to the Australian Securities Exchange (ASX). Our table below can help you choose.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, PayPal or debit card.
  3. Search for BARD1 Life Sciences. Find the share by name or ticker symbol: BD1. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until BARD1 Life Sciences reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At today's price of $0.027, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs.
  6. Check in on your investment. Congratulations, you own a part of BARD1 Life Sciences. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted BARD1 Life Sciences's share price?

Since the stock market crash in March caused by coronavirus, BARD1 Life Sciences's share price has had significant negative movement.

Its last market close was $0.027, which is 22.86% down on its pre-crash value of $0.035 and 42.11% up on the lowest point reached during the March crash when the shares fell as low as $0.019.

If you had bought $1,000 worth of BARD1 Life Sciences shares at the start of February 2020, those shares would have been worth $558.82 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $794.12.

BARD1 Life Sciences share price

Use our graph to track the performance of BD1 stocks over time.

BARD1 Life Sciences shares at a glance

Information last updated 2020-09-15.
Latest market closeAUDA$0.027
52-week rangeAUDA$0.019 - AUDA$0.056
50-day moving average AUDA$0.0303
200-day moving average AUDA$0.0273
Target priceN/A
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) AUDA$-0.001

Share Trading Account Offer

IG Share Trading Offer

AUD 8

Standard brokerage - Australian shares

Share Trading Account Offer

Competitive broker fees on Australian and international shares

  • Brokerage - AU shares: From AUD 5 or 0.05%
  • Brokerage - US shares: USD 0
  • Sign-up process: Instant
  • Support - After hours: Yes
Go to site
More info

Important: Share trading carries risk of capital loss.

Promoted

Compare share trading platforms

The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.
Data indicated here is updated regularly
Name Product Standard brokerage fee Inactivity fee Markets
IG Share Trading
Finder Award
IG Share Trading
AUD 8 or 0.1%
AUD 50 per quarter if you make fewer than three trades in that period
ASX shares, Global shares, Forex, CFDs, Margin trading
Brokerage discount: $5 on Australian shares for active traders & $0 commission on US and global shares
Enjoy some of the lowest brokerage fees on the market when trading Australian shares, international shares, forex and CFDs, plus get access to 24-hour customer support.
Bell Direct Share Trading
AUD 15 or 0.1%
No
ASX shares, mFunds
Special offer: Free ETF trades until September 30th when you join Bell Direct
Bell Direct offers a one-second placement guarantee on market-to-limit ASX orders or your trade is free, plus enjoy extensive free research reports from top financial experts.
Superhero share trading
$5 a trade
$0
ASX shares
Trade ASX stocks and ETFs with a flat $5 brokerage fee and a low minimum investment of just $100.
CMC Markets Stockbroking
AUD 11 or 0.1%
No
ASX shares, Global shares, Forex, CFDs, Margin trading, Options trading, mFunds
$0 brokerage on global shares including US, UK and Japan markets.
Trade up to 9,000 products, including shares, managed funds, forex, commodities and cryptocurrencies, plus access up to 15 major global and Australian stock exchanges.
ANZ Share Investing
AUD 19.95
No
ASX shares, Global shares, Margin trading, Options trading
Earn 1 Qantas Point per AU$3 spent on brokerage fees on certain instruments.
Access Morningstar reports, company announcements and and live pricing via ANZ’s share investing platform. Available for desktop and mobile.
Westpac Online Investing Account
AUD 19.95 or 0.11%
AUD 63.50 per year on the global markets account
ASX shares, Global shares, Options trading, US shares
loading

Compare up to 4 providers

Is it a good time to buy BARD1 Life Sciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

BARD1 Life Sciences price performance over time

Historical closes compared with the last close of A$0.027

1 week (2020-09-10) 0.027
1 month (2020-08-20) -12.90%
3 months (2020-06-19) -6.90%
6 months (2020-03-20) 28.57%
1 year (2019-09-20) -20.59%
2 years (2018-09-20) 152.34%
3 years (2017-09-20) 246.15%
5 years (2015-09-18) -7.22%

BARD1 Life Sciences financials

Revenue TTM $464,101
Gross profit TTM $-220,796
Return on assets TTM -20.26%
Return on equity TTM -47.81%
Profit margin 0%
Book value 0.005
Market capitalisation $67 million

TTM: trailing 12 months

BARD1 Life Sciences share dividends

We're not expecting BARD1 Life Sciences to pay a dividend over the next 12 months.

Have BARD1 Life Sciences's shares ever split?

BARD1 Life Sciences's shares were split on a 1:10 basis on 10 September 2008. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your BARD1 Life Sciences shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for BARD1 Life Sciences shares which in turn could have impacted BARD1 Life Sciences's share price.

BARD1 Life Sciences share price volatility

Over the last 12 months, BARD1 Life Sciences's shares have ranged in value from as little as $0.019 up to $0.056. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while BARD1 Life Sciences's is -1.5732. This would suggest that BARD1 Life Sciences's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, BARD1 Life Sciences has bucked the trend.

BARD1 Life Sciences overview

BARD1 Life Sciences Limited engages in the research and development of non-invasive diagnostic tests for early detection of cancer in Australia. The company offers hTERT test for diagnosis of bladder cancer, with the development-stage BARD1 autoantibody test for early detection of ovarian, breast and lung cancers; hTERT ICC test, an antibody-based immunocytochemistry stain that detects a component of telomerase; EXO-NET, a technology to capture and isolation of exosomes from any liquid biopsy sample; and BARD1 autoantibodies test to evaluate autoantibody panels and algorithms for detection of ovarian, breast and lung cancers. BARD1 Life Sciences Limited was incorporated in 1983 and is headquartered in South Perth, Australia.

Frequently asked questions

Ask an Expert

You are about to post a question on finder.com.au:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com.au is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder only provides general advice and factual information, so consider your own circumstances, or seek advice before you decide to act on our content. By submitting a question, you're accepting our Terms of Use, Disclaimer & Privacy Policy and Privacy & Cookies Policy.
Go to site